SEARCH

SEARCH BY CITATION

References

  • 1
    Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332:13028.
  • 2
    Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006;8:R153.
  • 3
    Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092102.
  • 4
    Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:107180.
  • 5
    FitzGerald GA. Coxibs Cardiovascular Disease. N Engl J Med 2004;351:28758.
  • 6
    Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today 2004;40:395414.
  • 7
    Watson DJ, Yu Q, Bolognese JA, et al. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin 2004;20:153948.
  • 8
    Baraf HSB, Fuentealba C, Greenwald M, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. J Rheumatol 2007; 34:40820.
  • 9
    Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369:46573.
  • 10
    Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006;152:23745.
  • 11
    Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368:177181.
  • 12
    Expert Panel on Detection EAToHBCIAATPI. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001;285:248697.
  • 13
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495504.
  • 14
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:22739.
  • 15
    The European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:177581.
  • 16
    Vollset SE, Refsum H, Tverdal A, et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001;74:1306.
  • 17
    Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999;33:134752.
  • 18
    Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:11836.
  • 19
    Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279: 147782.
  • 20
    Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41:37S42S.
  • 21
    Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:155765.
  • 22
    Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100:96102.
  • 23
    Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:3639.
  • 24
    Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004;109:IV6–19.
  • 25
    Maas R, Boger RH. Old and new cardiovascular risk factors: from unresolved issues to new opportunities. Atherosclerosis Supplements 2003;4:517.
  • 26
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:15208.
  • 27
    Blackwelder CW. Equivalence trials. In: ArmitageP, ColtonT, eds. Encyclopedia of biostatistics. Chichester: John Wiley; 1998:136772.
  • 28
    Piaggio G, Elbourne D, Altman D, Pocock SES. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:115260.
  • 29
    ICH Harmonised Tripartite Guideline Topic E9: Statistical Principles for clinical trails. 1999.
  • 30
    Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:18138.
  • 31
    Merck. In-house statistical analysis of the AFCAPS/TexCAPS data. 2002.
  • 32
    Ridker PM, Shih J, Cook TJ, et al. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 2002;105: 17769.
  • 33
    Wilson PWF, D'Agostino RB, Levy D, et al. Predication of coronary heart disease using risk factor categories. Circulation 1998;97:183747.
  • 34
    Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997;54:3240.
  • 35
    Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:415.
  • 36
    Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368:177181.
  • 37
    Clinical Trials Registry [database on internet]. Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen. Registration number: NCT00346216; Available at: http://www.clinicaltrials.gov/ct/show/NCT00346216?order=4 (accessed August 2, 2007).